Download a Free Sample To learn more about this report,
The China Cell and Gene Therapy Manufacturing QC Market size was valued at USD 824 million in 2025 and is projected to grow from USD 914 million in 2026 to USD 2.69 billion by 2034 at a CAGR of 14.4% during the forecast period 2026–2034.
In the past few years, with China's emphasis on innovation and the global rise in clinical trials involving these therapies, the country has become a key player in this sector. Additionally, the Chinese government's investment in biotech infrastructure and supportive regulatory framework has further accelerated the growth of this market.
The Chinese government's regulatory support has fueled the demand for QC in cell and gene therapy manufacturing. The National Medical Products Administration (NMPA) has streamlined the approval process for advanced therapies, fast-tracking innovative treatments. In 2021, the NMPA approved several investigational new drug (IND) applications for gene therapies, positioning China as a global leader in this domain.
Moreover, the regulatory body's alignment with international standards like Good Manufacturing Practices (GMP) ensures stringent QC measures, providing confidence in the quality and safety of these novel therapies. With over 1,000 active cell and gene therapy clinical trials in China as of 2023, the need for consistent QC has never been more urgent.
Despite the market's growth, one significant restraint is the high cost and complexity of quality control in cell and gene therapy manufacturing. These therapies are highly personalized, requiring stringent monitoring of every step, from cell culture to gene modification and product formulation. Quality control procedures involve sophisticated testing methods, such as next-generation sequencing (NGS) and flow cytometry, which can be expensive and resource-intensive.
For instance, a single batch of gene therapy can require up to 70 different tests, driving up costs and timelines. Furthermore, the lack of standardized QC processes adds to the complexity, as different products may require custom testing protocols. Small and mid-sized companies, in particular, may struggle with the financial and technical barriers posed by these rigorous requirements, limiting their industry participation.
China presents significant opportunities for partnerships between domestic companies and global biopharmaceutical firms, particularly in the QC segment. Several international companies are eyeing China as a strategic region due to its robust clinical trial landscape and manufacturing capabilities. In 2022, Gilead Sciences partnered with Chinese biopharma firm Fosun Kite to co-develop cell therapies, highlighting the growing trend of global collaboration in this sector.
These partnerships provide Chinese companies with access to advanced QC technologies and expertise, helping them align with international standards. Moreover, foreign companies benefit from China's cost-effective manufacturing and rapid clinical trial infrastructure. As a result, joint ventures and strategic partnerships are expected to boost the market for QC solutions in the coming years, fostering innovation and expanding the scope of cell and gene therapy manufacturing.
Vector Production dominates the workflow segment and is expected to augment at a CAGR of 27.8%. The vector production workflow segment is expanding rapidly in the China Market, driven by the growing need for viral vectors in gene therapy. As gene therapies proliferate, efficient vector production with high-quality control is crucial for delivering accurate, safe, and effective genetic material to patients.
Upstream Processes dominates the process segment and is estimated to grow at a CAGR of 26.5%. The upstream processes segment in the Market is witnessing robust growth due to increasing demand for cell culture and gene editing techniques. Advances in bioreactor technologies and improved cell growth monitoring are driving efficiency, making upstream QC critical for scalable therapeutic production.
Biopharmaceutical/biotechnological companies are estimated to own the end-user segment and are anticipated to expand at a CAGR of 26.5%. Biopharmaceutical and biotechnological companies are the fastest-growing end-users in this market due to their central role in developing, manufacturing, and commercializing advanced therapies. With rising clinical trials and R&D investments, these companies require stringent QC measures to ensure compliance and product safety.
Request Customizationto receive a tailored report.
Speak to an Analystto discuss market opportunities.
China dominates the Asia-Pacific region due to its advanced biotechnology infrastructure, regulatory support, and clinical trial activity. The country's growing emphasis on biopharmaceuticals has made it the largest hub for cell and gene therapy research in Asia. The Beijing-Tianjin-Hebei region and the Yangtze River Delta are key areas driving market growth, with several biotechnology parks and government-funded research institutes located in these regions. Additionally, the Guangdong-Hong Kong-Macao Greater Bay Area is emerging as a major center for biotech innovation, supported by substantial government funding and favorable policies.
Furthermore, The NMPA's close collaboration with international regulatory bodies, including the FDA and EMA, ensures that China's QC standards for cell and gene therapies align with global benchmarks, further solidifying the country's position in the global Cell and Gene Therapy Manufacturing QC market. Moreover, there has also been a rise in the strategic initiatives of the key players to advance this technique technologically.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Severity: Notice
Message: Undefined variable: relatedReports
Filename: reportpages/rd.php
Line Number: 640
Backtrace:
File: /var/www/html/application/views/frontend/reportpages/rd.php Line: 640 Function: _error_handler
File: /var/www/html/application/controllers/FrontendRegionalReportController.php Line: 108 Function: view
File: /var/www/html/index.php Line: 364 Function: require_once
We are featured on:
sales@straitsresearch.com